What is the most prominent clinical feature of Dilantin toxicity?

What is the most prominent clinical feature of Dilantin toxicity?

• A. Behavior changes
• B. Postural tremor
• C. Weakness
• D. Ataxia

Answer: (D)

The most prominent clinical feature of Dilantin (phenytoin) toxicity is ataxia. Ataxia refers to a lack of voluntary coordination of muscle movements, which can result in an unsteady gait and difficulty with fine motor tasks. This symptom arises due to the effects of Dilantin on the central nervous system and is particularly notable when the drug levels exceed the therapeutic range. Ataxia in the context of Dilantin toxicity occurs as a result of its sedative properties and the impact on cerebellar function, which is responsible for coordination and balance. Patients may exhibit difficulties in walking, maintaining balance, or performing tasks that require precise movements. Recognizing ataxia as a key indicator of toxicity is crucial for healthcare professionals, as it can guide the assessment and management of a patient on Dilantin therapy. Other symptoms associated with Dilantin toxicity may include behavior changes, postural tremors, and weakness, but ataxia stands out as the most significant and clinically observable feature that reflects the neurotoxic effects of elevated levels of the medication.

The most prominent clinical feature of Dilantin (phenytoin) toxicity is ataxia. Ataxia refers to a lack of voluntary coordination of muscle movements, which can result in an unsteady gait and difficulty with fine motor tasks. This symptom arises due to the effects of Dilantin on the central nervous system and is particularly notable when the drug levels exceed the therapeutic range.

Ataxia in the context of Dilantin toxicity occurs as a result of its sedative properties and the impact on cerebellar function, which is responsible for coordination and balance. Patients may exhibit difficulties in walking, maintaining balance, or performing tasks that require precise movements. Recognizing ataxia as a key indicator of toxicity is crucial for healthcare professionals, as it can guide the assessment and management of a patient on Dilantin therapy.

Other symptoms associated with Dilantin toxicity may include behavior changes, postural tremors, and weakness, but ataxia stands out as the most significant and clinically observable feature that reflects the neurotoxic effects of elevated levels of the medication.